Growing R&D Portfolio SIGA's focus on developing treatments for high-demand emerging infectious diseases like smallpox, mpox, and orthopoxviruses presents opportunities for partnerships with healthcare providers, governments, and international health agencies seeking advanced biodefense solutions.

Strategic Collaborations Recent partnerships with Vanderbilt University and Calidi Biotherapeutics demonstrate SIGA's openness to innovative collaborations, which could be expanded to include commercialization and distribution channels in military, public health, and biotech sectors.

Government Engagement Ongoing collaborations with the Department of Defense support SIGA’s products such as TPOXX and suggest potential for government procurement contracts and public sector sales, especially within biodefense and pandemic preparedness portfolios.

Market Expansion Potential With a focus on developing post-exposure prophylaxis and monoclonal antibodies for poxviruses, SIGA’s products are aligned with increasing global biosecurity needs, offering growth opportunities in both domestic and international markets.

Financial and Investment Appeal Although revenue remains modest, SIGA's recent funding and high-impact product pipeline make it an attractive partner for investors and organizations interested in supporting innovative biotech solutions addressing unmet medical and biodefense needs.